Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 124
- Registration Number
- NCT02660424
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: TEZ/IVADrug: IVA
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1131
- Registration Number
- NCT02565914
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 246
- Registration Number
- NCT02544451
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: VX-661 plus ivacaftor combinationDrug: Placebo (matched to VX-661 plus ivacaftor combination)Drug: Placebo (matched to ivacaftor)
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 168
- Registration Number
- NCT02516410
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 206
- Registration Number
- NCT02514473
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Tezacaftor/Ivacaftor matching placebo
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 34
- Registration Number
- NCT02508207
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 75
- Registration Number
- NCT02445053
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 156
- Registration Number
- NCT02412111
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: VX-661/IvacaftorDrug: Placebo matched to VX-661/ ivacaftorDrug: Placebo matched to Ivacaftor
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 248
- Registration Number
- NCT02392234
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
Phase 3
Completed
- Conditions
- Cystic FibrosisAdvanced Lung Disease
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 46
- Registration Number
- NCT02390219